Atlas Trials

A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

Clinical trial NCT07692048 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07692048
Sponsor
Sichuan University
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
NSCLC
Start date
2026-06-30
Primary completion
2027-12-31
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.